Summary

The metered dose inhalers market was valued at $10,081.4 million in 2024 and is estimated to reach $18,406.27 million by 2034, exhibiting a CAGR of 6.2% from 2025 to 2034.
A Metered Dose Inhaler (MDI) is a device commonly used to deliver medications directly to the lungs, primarily for conditions like asthma, COPD (chronic obstructive pulmonary disease), and other respiratory disorders. These inhalers consist of a pressurized canister containing medication, which is released through a mouthpiece when the canister is actuated. The medication is usually in the form of an aerosol or suspension that is inhaled during a breath, ensuring rapid absorption in the lungs. MDIs are widely preferred due to their compact design, ease of use, and ability to provide quick relief from symptoms like wheezing, coughing, and shortness of breath. In recent years, advances such as dose counters, breath-actuated mechanisms, and environmentally friendly propellants have enhanced the effectiveness and safety of MDIs. They play a critical role in both emergency and maintenance therapy for millions of patients worldwide, particularly in outpatient and home care settings.

Rise in aging population, improved compliance, environmental regulations, and generic availability are fueling steady growth in the global metered dose inhalers market. Moreover, initiatives taken by key industry players are further contributing to the market’s positive trajectory. For instance, in January 2023, the Hormosan Pharma GmbH (Hormosan), Lupin’s wholly-owned subsidiary in Germany, announced the launch of Luforbec 100/6 (beclometasone 100µg / for moterol 6µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. 
Moreover, to reduce the environmental impact of inhalers, pharmaceutical companies are transitioning to low-global warming potential (GWP) propellants. For instance, Kindeva Drug Delivery is set to produce MDIs using propellants like HFA-152a and HFO-1234ze, which offer GWP reductions of up to 90% and 99.9%, respectively, compared to the traditional HFA-134a . In addition, artificial Intelligence (AI) is being utilized to optimize drug delivery. Machine learning algorithms analyze factors such as breathing profiles and disease status to adjust inhaler settings, ensuring targeted drug release to specific lung sites while minimizing side effects. With companies actively developing new formulations and expanding their product portfolios, the metered dose inhalers market is expected to continue witnessing robust growth in the coming years.

Segment Overview:
The metered dose inhalers market is segmented on the basis of product type, application, distribution channel, and region. On the basis of product type the market is segmented into conventional MDIs, and breath-actuated MDIs. On the basis of application, the market is segmented into asthma, COPD and others. On the basis of distribution channel, the market is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). 
The major key players that operate in the global metered dose inhalers market are AstraZeneca, GlaxoSmithKline Pharmaceuticals Ltd, Chiesi Farmaceutici S.p.A., Cipla Ltd., Teva Pharmaceutical Industries, Lupin, AptarGroup, Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., and Zydus Lifesciences Limited.
 
Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Additional company profiles with specific to client's interest
● Expanded list for Company Profiles
● Historic market data

Key Market Segments
By Application
● Asthma
● COPD
● Other

By Distribution Channel
● Hospital Pharmacies
● Retail Pharmacies
● Online Pharmacies

By Product Type
● Conventional MDIs
● Breath actuated MDIs

By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Rest of Asia-Pacific
● LAMEA○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA

● Key Market Players
○ AstraZeneca
○ Cipla Ltd.
○ Teva Pharmaceutical Industries
○ Lupin
○ Boehringer Ingelheim International GmbH
○ Zydus Lifesciences Limited
○ Chiesi Farmaceutici S.p.A.
○ GlaxoSmithKline Pharmaceuticals Ltd
○ AptarGroup, Inc.
○ Sun Pharmaceutical Industries Ltd.

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION

1.1. Report description


1.2. Key market segments


1.3. Key benefits to the stakeholders


1.4. Research methodology

1.4.1. Primary research


1.4.2. Secondary research


1.4.3. Analyst tools and models


CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective


CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope


3.2. Key findings

3.2.1. Top impacting factors


3.2.2. Top investment pockets


3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers

3.3.2. Moderate threat of new entrants

3.3.3. Moderate threat of substitutes

3.3.4. Moderate intensity of rivalry

3.3.5. Moderate bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of respiratory diseases

3.4.1.2. Availability of generic and low-cost inhalers

3.4.1.3. Technological advancements in metered dose inhalers

3.4.2. Restraints

3.4.2.1. Challenges in Patient Awareness and Regulatory Approvals

3.4.3. Opportunities

3.4.3.1. Development of eco-friendly inhalers

CHAPTER 4: METERED DOSE INHALERS MARKET, BY PRODUCT TYPE
4.1. Overview

4.1.1. Market size and forecast

4.2. Conventional MDIs
4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Breath actuated MDIs
4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

CHAPTER 5: METERED DOSE INHALERS MARKET, BY APPLICATION
5.1. Overview

5.1.1. Market size and forecast

5.2. Asthma
5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. COPD
5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Other
5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

CHAPTER 6: METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Online Pharmacies
6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

CHAPTER 7: METERED DOSE INHALERS MARKET, BY REGION
7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America
7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by Product Type

7.2.3. Market size and forecast, by Application

7.2.4. Market size and forecast, by Distribution Channel

7.2.5. Market size and forecast, by country
7.2.5.1. U.S.

7.2.5.1.1. Market size and forecast, by Product Type
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by Distribution Channel

7.2.5.2. Canada

7.2.5.2.1. Market size and forecast, by Product Type
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by Distribution Channel

7.2.5.3. Mexico

7.2.5.3.1. Market size and forecast, by Product Type
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by Distribution Channel

7.3. Europe
7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by Product Type

7.3.3. Market size and forecast, by Application

7.3.4. Market size and forecast, by Distribution Channel

7.3.5. Market size and forecast, by country
7.3.5.1. Germany

7.3.5.1.1. Market size and forecast, by Product Type
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by Distribution Channel

7.3.5.2. France

7.3.5.2.1. Market size and forecast, by Product Type
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by Distribution Channel

7.3.5.3. UK

7.3.5.3.1. Market size and forecast, by Product Type
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by Distribution Channel

7.3.5.4. Italy

7.3.5.4.1. Market size and forecast, by Product Type
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by Distribution Channel

7.3.5.5. Spain

7.3.5.5.1. Market size and forecast, by Product Type
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by Distribution Channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Market size and forecast, by Product Type
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by Distribution Channel

7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by Product Type

7.4.3. Market size and forecast, by Application

7.4.4. Market size and forecast, by Distribution Channel

7.4.5. Market size and forecast, by country
7.4.5.1. Japan

7.4.5.1.1. Market size and forecast, by Product Type
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by Distribution Channel

7.4.5.2. China

7.4.5.2.1. Market size and forecast, by Product Type
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by Distribution Channel

7.4.5.3. India

7.4.5.3.1. Market size and forecast, by Product Type
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by Distribution Channel

7.4.5.4. Australia

7.4.5.4.1. Market size and forecast, by Product Type
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by Distribution Channel

7.4.5.5. South Korea

7.4.5.5.1. Market size and forecast, by Product Type
7.4.5.5.2. Market size and forecast, by Application
7.4.5.5.3. Market size and forecast, by Distribution Channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Market size and forecast, by Product Type
7.4.5.6.2. Market size and forecast, by Application
7.4.5.6.3. Market size and forecast, by Distribution Channel

7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities

7.5.2. Market size and forecast, by Product Type

7.5.3. Market size and forecast, by Application

7.5.4. Market size and forecast, by Distribution Channel

7.5.5. Market size and forecast, by country
7.5.5.1. Brazil

7.5.5.1.1. Market size and forecast, by Product Type
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by Distribution Channel

7.5.5.2. Saudi Arabia

7.5.5.2.1. Market size and forecast, by Product Type
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by Distribution Channel

7.5.5.3. South Africa

7.5.5.3.1. Market size and forecast, by Product Type
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by Distribution Channel

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Market size and forecast, by Product Type
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction

8.2. Top winning strategies

8.3. Product mapping of top 10 player

8.4. Competitive dashboard

8.5. Competitive heatmap

8.6. Top player positioning, 2024

CHAPTER 9: COMPANY PROFILES
9.1. AstraZeneca
9.1.1. Company overview

9.1.2. Key executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. GlaxoSmithKline Pharmaceuticals Ltd
9.2.1. Company overview

9.2.2. Key executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. Chiesi Farmaceutici S.p.A.
9.3.1. Company overview

9.3.2. Key executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.4. Cipla Ltd.
9.4.1. Company overview

9.4.2. Key executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. Teva Pharmaceutical Industries
9.5.1. Company overview

9.5.2. Key executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.6. Lupin
9.6.1. Company overview

9.6.2. Key executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.6.7. Key strategic moves and developments

9.7. AptarGroup, Inc.
9.7.1. Company overview

9.7.2. Key executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. Boehringer Ingelheim International GmbH
9.8.1. Company overview

9.8.2. Key executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Sun Pharmaceutical Industries Ltd.
9.9.1. Company overview

9.9.2. Key executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. Zydus Lifesciences Limited
9.10.1. Company overview

9.10.2. Key executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performance